A new inactivated tissue culture rabies vaccine for use in man Evaluation of PCEC-vaccine by laboratory tests

Barth, R; Gruschkau, H; Bijok, U.; Hilfenhaus, J.; Hinz, Joann M.; L, Milcke; Moser, Hans; O, Jaeger; Ronneberger, H.; Weinmann, E.

doi:10.1016/s0092-1157(84)80019-0

Cited by 45 publications

(17 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It results in high production costs and a limited output of vaccine for HDCV [29]. Over subsequent years, a series of different vaccines have been developed with similar immunogenicity to HDCV [12].…”

mentioning

confidence: 99%

See 1 more Smart Citation

30 years of rabies vaccination with Rabipur: a summary of clinical data and global experience

Giesen

Gniel

Malerczyk

2015

Expert Review of Vaccines

View full text Add to dashboard Cite

mentioning

confidence: 99%

“…In the 1980s, an immunogenic PCECV containing inactivated rabies virus (LEP Flury strain) was developed. In a series of animal laboratory tests, PCECV showed comparable immunogenicity and tolerability to that of HDCV [29]. In human studies, PCECV induced similar immunogenicity to HDCV [31][32][33][34].…”

mentioning

confidence: 99%

30 years of rabies vaccination with Rabipur: a summary of clinical data and global experience

Giesen

Gniel

Malerczyk

2015

Expert Review of Vaccines

View full text Add to dashboard Cite

“…9 The first PCECV, Rabipur was developed using Flury-LEP strain which was already adapted to grow in chick embryo by Barth. 10 Rabipur has been found to be efficacious in preventing rabies in exposed individuals both by conventional IM and the ID routes of vaccination and has been recommended by WHO. 11 Recent studies based on genetic characterization of different vaccine strains have shown close homology between Flury LEP and Pittman-Moore strain.…”

Section: Discussionmentioning

confidence: 99%

Safety and Immunogenicity of purified chick embryo cell rabies vaccine (VaxiRab N) administered intradermally as post exposure prophylaxis

Ravish

Vijayashankar

Madhusudana

et al. 2014

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

“…However, the lower virus yields and higher production costs make the human diploid cell vaccine difficult to scale up and can be generally unaffordable to most developing countries, where the majority of human deaths from rabies occur. As an alternative, other cell culture vaccines, such as the purified duck/chick embryo cell vaccine, were developed and proved to be as effective as human diploid cell vaccine, and are now commonly used for human rabies prevention worldwide [21,22,23]. Nevertheless, as the primary culture cells inherently have a limited capacity to divide, they are technically difficult to adapt to large-scale industrial cultivation for vaccine manufacturing.…”

Section: Brief History Of Classical Rabies Vaccinesmentioning

confidence: 99%

Rabies Control and Treatment: From Prophylaxis to Strategies with Curative Potential

Zhu

Guo

2016

Viruses

View full text Add to dashboard Cite

Rabies is an acute, fatal, neurological disease that affects almost all kinds of mammals. Vaccination (using an inactivated rabies vaccine), combined with administration of rabies immune globulin, is the only approved, effective method for post-exposure prophylaxis against rabies in humans. In the search for novel rabies control and treatment strategies, live-attenuated viruses have recently emerged as a practical and promising approach for immunizing and controlling rabies. Unlike the conventional, inactivated rabies vaccine, live-attenuated viruses are genetically modified viruses that are able to replicate in an inoculated recipient without causing adverse effects, while still eliciting robust and effective immune responses against rabies virus infection. A number of viruses with an intrinsic capacity that could be used as putative candidates for live-attenuated rabies vaccine have been intensively evaluated for therapeutic purposes. Additional novel strategies, such as a monoclonal antibody-based approach, nucleic acid-based vaccines, or small interfering RNAs (siRNAs) interfering with virus replication, could further add to the arena of strategies to combat rabies. In this review, we highlight current advances in rabies therapy and discuss the role that they might have in the future of rabies treatment. Given the pronounced and complex impact of rabies on a patient, a combination of these novel modalities has the potential to achieve maximal anti-rabies efficacy, or may even have promising curative effects in the future. However, several hurdles regarding clinical safety considerations and public awareness should be overcome before these approaches can ultimately become clinically relevant therapies.

show abstract

A new inactivated tissue culture rabies vaccine for use in man Evaluation of PCEC-vaccine by laboratory tests

Cited by 45 publications

References 13 publications

30 years of rabies vaccination with Rabipur: a summary of clinical data and global experience

30 years of rabies vaccination with Rabipur: a summary of clinical data and global experience

Safety and Immunogenicity of purified chick embryo cell rabies vaccine (VaxiRab N) administered intradermally as post exposure prophylaxis

Rabies Control and Treatment: From Prophylaxis to Strategies with Curative Potential

Contact Info

Product

Resources

About